Transdermal testosterone therapy in the treatment of male hypogonadism

S. Rafeeq Ahmed, Alice E. Boucher, Andrea Manni, Richard J. Santen, Mary Bartholomew, Laurence M. Demers

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Five hypogonadal men were treated with transdermal testosterone therapy, using a testosterone patch applied to the scrotal skin. Daily application of the patch, which contained 10 mg testosterone, produced an increase in serum testosterone concentrations from a pretreatment value of 45 ± 12 (±SE; 1.5 ± 0.4) to 436 ± 80 ng/dL (15.1 ± 2.8 nmol/L; P < 0.001) after 4 weeks of treatment. Normal serum testosterone concentrations were achieved in all men after 6-8 weeks of therapy and were maintained during continued long term therapy for 9-12 months with a patch containing 15 mg testosterone. All men reported a subjective increase in libido and sexual function during therapy, and three men preferred it to testosterone injections. The serum testosterone and estradiol levels did not rise above the normal adult male range at any time during therapy. However, elevated serum dihydrotestosterone (DHT) concentrations occurred during treatment; the pretreatment DHT concentration was 95 ± 3 ng/dL (3.3 ± 0.1 nmol/L), and it increased to 228 ± 40 ng/dL (7.8 ± 1.4 nmol/L) after 4 weeks of treatment and remained elevated thereafter. The individual mean DHT to testosterone ratio increased from a pretreatment value of 0.2 (range, 0.1-0.3) to 0.6 (range, 0.4-0.7) after 2 weeks of therapy and remained high thereafter. Comparison of the serum DHT levels in patients during therapy with those in normal men who had similar testosterone concentrations [531 ± 62 vs. 566 ± 72 ng/dL (18.4 ± 2.1 vs. 19.6 ± 2.5 nmol/L); P > 0.05] revealed that the mean serum DHT concentration was significantly higher in the patients [315 ± 69 vs. 87 ± 6 ng/dL (10.8 ± 2.4 vs. 2.9 ± 0.2 nmol/L); P < 0.001], as was the mean DHT to testosterone ratio [0.6 (range, 0.25- 1.1) vs. 0.16 (range, 0.09- 0.24); P < 0.001]. The high serum DHT levels presumably were due to increased metabolism of testosterone to DHT by the 5α-reductase in the scrotal skin. Serum 3α-androstanediol glucuronide levels were not elevated in the patients. We conclude that transdermal testosterone therapy is an effective long term treatment for hypogonadism in men. It is, however, associated with high serum DHT levels, whose potential long term effects on the prostate and other tissues need to be investigated.

Original languageEnglish (US)
Pages (from-to)546-551
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume66
Issue number3
DOIs
StatePublished - Mar 1988

Fingerprint

Eunuchism
Testosterone
Serum
Therapeutics
Skin
Hypogonadism
Glucuronides
Metabolism
Prostate
Oxidoreductases
Tissue

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Ahmed, S. Rafeeq ; Boucher, Alice E. ; Manni, Andrea ; Santen, Richard J. ; Bartholomew, Mary ; Demers, Laurence M. / Transdermal testosterone therapy in the treatment of male hypogonadism. In: Journal of Clinical Endocrinology and Metabolism. 1988 ; Vol. 66, No. 3. pp. 546-551.
@article{813c733849ad4030b2420878f08ec9fd,
title = "Transdermal testosterone therapy in the treatment of male hypogonadism",
abstract = "Five hypogonadal men were treated with transdermal testosterone therapy, using a testosterone patch applied to the scrotal skin. Daily application of the patch, which contained 10 mg testosterone, produced an increase in serum testosterone concentrations from a pretreatment value of 45 ± 12 (±SE; 1.5 ± 0.4) to 436 ± 80 ng/dL (15.1 ± 2.8 nmol/L; P < 0.001) after 4 weeks of treatment. Normal serum testosterone concentrations were achieved in all men after 6-8 weeks of therapy and were maintained during continued long term therapy for 9-12 months with a patch containing 15 mg testosterone. All men reported a subjective increase in libido and sexual function during therapy, and three men preferred it to testosterone injections. The serum testosterone and estradiol levels did not rise above the normal adult male range at any time during therapy. However, elevated serum dihydrotestosterone (DHT) concentrations occurred during treatment; the pretreatment DHT concentration was 95 ± 3 ng/dL (3.3 ± 0.1 nmol/L), and it increased to 228 ± 40 ng/dL (7.8 ± 1.4 nmol/L) after 4 weeks of treatment and remained elevated thereafter. The individual mean DHT to testosterone ratio increased from a pretreatment value of 0.2 (range, 0.1-0.3) to 0.6 (range, 0.4-0.7) after 2 weeks of therapy and remained high thereafter. Comparison of the serum DHT levels in patients during therapy with those in normal men who had similar testosterone concentrations [531 ± 62 vs. 566 ± 72 ng/dL (18.4 ± 2.1 vs. 19.6 ± 2.5 nmol/L); P > 0.05] revealed that the mean serum DHT concentration was significantly higher in the patients [315 ± 69 vs. 87 ± 6 ng/dL (10.8 ± 2.4 vs. 2.9 ± 0.2 nmol/L); P < 0.001], as was the mean DHT to testosterone ratio [0.6 (range, 0.25- 1.1) vs. 0.16 (range, 0.09- 0.24); P < 0.001]. The high serum DHT levels presumably were due to increased metabolism of testosterone to DHT by the 5α-reductase in the scrotal skin. Serum 3α-androstanediol glucuronide levels were not elevated in the patients. We conclude that transdermal testosterone therapy is an effective long term treatment for hypogonadism in men. It is, however, associated with high serum DHT levels, whose potential long term effects on the prostate and other tissues need to be investigated.",
author = "Ahmed, {S. Rafeeq} and Boucher, {Alice E.} and Andrea Manni and Santen, {Richard J.} and Mary Bartholomew and Demers, {Laurence M.}",
year = "1988",
month = "3",
doi = "10.1210/jcem-66-3-546",
language = "English (US)",
volume = "66",
pages = "546--551",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

Transdermal testosterone therapy in the treatment of male hypogonadism. / Ahmed, S. Rafeeq; Boucher, Alice E.; Manni, Andrea; Santen, Richard J.; Bartholomew, Mary; Demers, Laurence M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 66, No. 3, 03.1988, p. 546-551.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Transdermal testosterone therapy in the treatment of male hypogonadism

AU - Ahmed, S. Rafeeq

AU - Boucher, Alice E.

AU - Manni, Andrea

AU - Santen, Richard J.

AU - Bartholomew, Mary

AU - Demers, Laurence M.

PY - 1988/3

Y1 - 1988/3

N2 - Five hypogonadal men were treated with transdermal testosterone therapy, using a testosterone patch applied to the scrotal skin. Daily application of the patch, which contained 10 mg testosterone, produced an increase in serum testosterone concentrations from a pretreatment value of 45 ± 12 (±SE; 1.5 ± 0.4) to 436 ± 80 ng/dL (15.1 ± 2.8 nmol/L; P < 0.001) after 4 weeks of treatment. Normal serum testosterone concentrations were achieved in all men after 6-8 weeks of therapy and were maintained during continued long term therapy for 9-12 months with a patch containing 15 mg testosterone. All men reported a subjective increase in libido and sexual function during therapy, and three men preferred it to testosterone injections. The serum testosterone and estradiol levels did not rise above the normal adult male range at any time during therapy. However, elevated serum dihydrotestosterone (DHT) concentrations occurred during treatment; the pretreatment DHT concentration was 95 ± 3 ng/dL (3.3 ± 0.1 nmol/L), and it increased to 228 ± 40 ng/dL (7.8 ± 1.4 nmol/L) after 4 weeks of treatment and remained elevated thereafter. The individual mean DHT to testosterone ratio increased from a pretreatment value of 0.2 (range, 0.1-0.3) to 0.6 (range, 0.4-0.7) after 2 weeks of therapy and remained high thereafter. Comparison of the serum DHT levels in patients during therapy with those in normal men who had similar testosterone concentrations [531 ± 62 vs. 566 ± 72 ng/dL (18.4 ± 2.1 vs. 19.6 ± 2.5 nmol/L); P > 0.05] revealed that the mean serum DHT concentration was significantly higher in the patients [315 ± 69 vs. 87 ± 6 ng/dL (10.8 ± 2.4 vs. 2.9 ± 0.2 nmol/L); P < 0.001], as was the mean DHT to testosterone ratio [0.6 (range, 0.25- 1.1) vs. 0.16 (range, 0.09- 0.24); P < 0.001]. The high serum DHT levels presumably were due to increased metabolism of testosterone to DHT by the 5α-reductase in the scrotal skin. Serum 3α-androstanediol glucuronide levels were not elevated in the patients. We conclude that transdermal testosterone therapy is an effective long term treatment for hypogonadism in men. It is, however, associated with high serum DHT levels, whose potential long term effects on the prostate and other tissues need to be investigated.

AB - Five hypogonadal men were treated with transdermal testosterone therapy, using a testosterone patch applied to the scrotal skin. Daily application of the patch, which contained 10 mg testosterone, produced an increase in serum testosterone concentrations from a pretreatment value of 45 ± 12 (±SE; 1.5 ± 0.4) to 436 ± 80 ng/dL (15.1 ± 2.8 nmol/L; P < 0.001) after 4 weeks of treatment. Normal serum testosterone concentrations were achieved in all men after 6-8 weeks of therapy and were maintained during continued long term therapy for 9-12 months with a patch containing 15 mg testosterone. All men reported a subjective increase in libido and sexual function during therapy, and three men preferred it to testosterone injections. The serum testosterone and estradiol levels did not rise above the normal adult male range at any time during therapy. However, elevated serum dihydrotestosterone (DHT) concentrations occurred during treatment; the pretreatment DHT concentration was 95 ± 3 ng/dL (3.3 ± 0.1 nmol/L), and it increased to 228 ± 40 ng/dL (7.8 ± 1.4 nmol/L) after 4 weeks of treatment and remained elevated thereafter. The individual mean DHT to testosterone ratio increased from a pretreatment value of 0.2 (range, 0.1-0.3) to 0.6 (range, 0.4-0.7) after 2 weeks of therapy and remained high thereafter. Comparison of the serum DHT levels in patients during therapy with those in normal men who had similar testosterone concentrations [531 ± 62 vs. 566 ± 72 ng/dL (18.4 ± 2.1 vs. 19.6 ± 2.5 nmol/L); P > 0.05] revealed that the mean serum DHT concentration was significantly higher in the patients [315 ± 69 vs. 87 ± 6 ng/dL (10.8 ± 2.4 vs. 2.9 ± 0.2 nmol/L); P < 0.001], as was the mean DHT to testosterone ratio [0.6 (range, 0.25- 1.1) vs. 0.16 (range, 0.09- 0.24); P < 0.001]. The high serum DHT levels presumably were due to increased metabolism of testosterone to DHT by the 5α-reductase in the scrotal skin. Serum 3α-androstanediol glucuronide levels were not elevated in the patients. We conclude that transdermal testosterone therapy is an effective long term treatment for hypogonadism in men. It is, however, associated with high serum DHT levels, whose potential long term effects on the prostate and other tissues need to be investigated.

UR - http://www.scopus.com/inward/record.url?scp=0023850372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023850372&partnerID=8YFLogxK

U2 - 10.1210/jcem-66-3-546

DO - 10.1210/jcem-66-3-546

M3 - Article

C2 - 3350906

AN - SCOPUS:0023850372

VL - 66

SP - 546

EP - 551

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -